- Trial phase
- Phase 2 (Phase 2/3 HexAgon-HN study)
- Time to market
- If the Phase 2 expansion data supports accelerated approval discussions, a BLA filing could follow in 2027-2028, with potential approval in 2028-2029 for HNSCC. The Phase 3 portion of the HexAgon-HN study is already ongoing.
- Why 5/10
- The next hard catalyst for ordastobart is the Phase 2 expansion readout in HNSCC expected mid-2027 (~7 months away), which is a non-pivotal expansion cohort readout at a company that also has ozekibart (INBRX-109) with an April 2027 PDUFA date, limiting the binary impact of this single drug.
Watch for the Phase 2 expansion readout in HNSCC expected mid-2027, which will show whether the strong Phase 2 interim data (48.3% cORR, 9.6-month PFS) holds in a larger cohort. Positive data could support accelerated approval discussions; negative data would undercut the pipeline thesis. Also monitor the ozekibart PDUFA date of April 14, 2027, which is the company's nearer-term binary catalyst.
Price Chart
Executive Summary
Ordastobart (INBRX-106) is Inhibrx Biosciences' hexavalent OX40 agonist immunotherapy in Phase 2/3 development for first-line head and neck squamous cell carcinoma (HNSCC) and Phase 1/2 for perioperative non-small cell lung cancer (NSCLC). In September 2026, the randomized Phase 2 HexAgon study showed ordastobart plus pembrolizumab nearly doubled the confirmed objective response rate (48.3% vs 26.5%) and achieved 9.6-month median progression-free survival versus pembrolizumab alone, making it the first OX40 agonist to demonstrate clinical benefit in a randomized trial. The drug was also presented at ESMO 2026. The next catalyst is the Phase 2 expansion readout in HNSCC expected mid-2027, with a Phase 1/2 NSCLC readout also expected around the same time. Inhibrx trades at $83.30 with a $1.33B market cap, $199.5M cash, and $276.7M debt, with analyst consensus strongly bullish (8 Buy/Strong Buy, mean target $266.67).
How It Works
Ordastobart is a lab-designed antibody-like molecule that activates OX40, a protein on the surface of immune T-cells. By turning on OX40, it stimulates T-cells to multiply and attack cancer cells more aggressively. It is given in combination with pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor, to boost the immune response against head and neck and lung cancers.
Trial Status
The randomized Phase 2 portion of the HexAgon-HN study in first-line HNSCC met its primary endpoint in September 2026, showing a 48.3% cORR and 9.6-month median PFS for ordastobart plus pembrolizumab. The Phase 2 expansion cohort is enrolling, with initial readout expected mid-2027. A Phase 1/2 study in perioperative NSCLC is also ongoing with results expected mid-2027. Data was presented at ESMO 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 expansion readout in HNSCC expected mid-2027
- Phase 1/2 perioperative NSCLC results expected mid-2027
- Potential accelerated approval discussions if expansion data remains strong
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Inhibrx Biosciences, Inc. PRESS-RELEASE INBX ·Originating report